VH-499 Capsid Inhibitor Shows Potent Viral Suppression in Early HIV Trial
A new oral HIV drug, VH-499, demonstrated potent antiviral activity and a favorable safety profile in a phase 2a trial involving 23 adults. The drug, developed by ViiV Healthcare, works by inhibiting the viral capsid and avoids interfering with the CYP3A4 enzyme, potentially offering advantages for patients with complex medication regimens compared to existing long-acting therapies like lenacapavir.